KR20000024485A - Cosmetic composition for the prevention and reduction of atopic dermatitis - Google Patents
Cosmetic composition for the prevention and reduction of atopic dermatitis Download PDFInfo
- Publication number
- KR20000024485A KR20000024485A KR1020000007277A KR20000007277A KR20000024485A KR 20000024485 A KR20000024485 A KR 20000024485A KR 1020000007277 A KR1020000007277 A KR 1020000007277A KR 20000007277 A KR20000007277 A KR 20000007277A KR 20000024485 A KR20000024485 A KR 20000024485A
- Authority
- KR
- South Korea
- Prior art keywords
- atopic dermatitis
- nicotinamide
- skin
- cosmetic composition
- effect
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B43—WRITING OR DRAWING IMPLEMENTS; BUREAU ACCESSORIES
- B43K—IMPLEMENTS FOR WRITING OR DRAWING
- B43K29/00—Combinations of writing implements with other articles
- B43K29/005—Combinations of writing implements with other articles with sound or noise making devices, e.g. radio, alarm
Abstract
Description
본 발명은 니코틴아미드(Nicotinamide)를 함유하는, 아토피성 피부염 완화를 목적으로 하는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing nicotinamide for the purpose of alleviating atopic dermatitis.
피부 건조증은 겨울철에 아주 흔히 발생되나 병인에 대하여서는 현재까지도 완전히 설명되지 않고 있다. 건조피부는 피부에 수분이 부족하거나 없는 상태를 일컬으며 임상적인 증세로는 경한 홍반과 균열이 있고 인설이 있는 표면이 거친 피부를 보인다. 건조 피부와 연관된 피부 질환으로는 아토피 피부염, 어린선, 건피증, 건성습진등이 대표적이고 노인층에서는 뚜렷한 피부 병변없이 건조 피부가 호발된다.Dry skin is very common in winter, but the etiology is still not fully explained. Dry skin refers to a condition in which the skin lacks or lacks moisture. Clinical symptoms include mild erythema, cracks, and rough skin. Skin diseases associated with dry skin include atopic dermatitis, young skin, dry skin and dry eczema, and dry skin is called in the elderly without obvious skin lesions.
일반적으로 아토피성 피부염은 피부 건조증을 동반하는 대표적인 질환으로 피부 장벽의 결함을 보이고 피부내 수분 보유량이 정상인에 비해 확연히 떨어져 있다고 보고된 바 있다.In general, atopic dermatitis is a representative disease accompanied by dry skin, and it has been reported that the skin barrier is defective and water retention in the skin is significantly lower than that of normal people.
또한, 아토피성 피부염은 아토피성 체질을 가진 사람에서 발생하는 만성 피부염으로 체질적인 문제이므로 근본적인 치료는 이루어지기 힘들며 병변의 상태에 따라 적절히 조절을 필요로 하는 질병이다. 그러나 아토피성 피부염은 연령과 더불어 약화되어 중년이후에는 드물다.In addition, atopic dermatitis is a chronic dermatitis that occurs in a person with atopic dermatitis, so it is a constitution problem, so the fundamental treatment is difficult to achieve and is a disease that requires appropriate control according to the condition of the lesion. However, atopic dermatitis weakens with age and rarely occurs after middle age.
아토피성 피부염 환자에서는 피부의 건조가 자주 동반되고 특히 겨울에는 피부가 건조해지므로 비누, 친수연고, 로션의 사용을 피해야 한다. 또한 환부에 이차적으로 세균이 감염되어 그 증상이 더욱 심해진다.In patients with atopic dermatitis, dry skin is often accompanied, especially in winter, so soap, hydrophilic ointment and lotion should be avoided. In addition, the secondary infection of the affected area is more severe symptoms.
현재까지 사용되는 치료 방법은 항알러지 효과를 보이는 제재를 사용하거나, 피부의 세포간 지질막을 강화하는 방법 그리고 항균작용이 있는 제재를 사용하여 피부염의 정도를 완화시키는 방법이 이용되고 있다.The treatment methods used up to now are using antiallergic agents, strengthening intercellular lipid membranes of skin, and using antimicrobial agents to alleviate the degree of dermatitis.
이에 본 발명자들은 화장료에 배합시 그 안정성과 안전성이 뛰어난 동시에 아토피성 피부의 완화효과가 탁월한 물질에 대한 연구를 진행하던 중에 니코틴아미드가 아토피성 피부염관련 주요 감염 세균들에 항균 작용이 뛰어난 점을 새로 밝혀 2차 감염에 의한 피부염 증상을 완화시키는 효과 및 제형내에서 안정성과 안전성이 매우 탁월함을 발견하였고, 사람을 대상으로 하는 실험에서 그 효과가 입증되어 본 발명을 완성하게 되었다.Therefore, the inventors of the present invention, while conducting a study on a material having excellent stability and safety when combined with cosmetics and an excellent effect of relieving atopic dermatitis, has found that nicotinamide has an excellent antibacterial effect on the major infectious bacteria related to atopic dermatitis. It was found that the effect of alleviating the symptoms of dermatitis caused by the secondary infection and stability and safety in the formulation was very excellent, the effect was proved in human experiments to complete the present invention.
본 발명은 니코틴아미드를 함유하는, 아토피성 피부염 완화용 화장료 조성물을 제공함을 특징으로 한다.The present invention is characterized by providing a cosmetic composition for atopic dermatitis relief, containing nicotinamide.
니코틴아미드는 분자량 117의 수용성 물질이며, 생체내에서는 비타민B로 전환되고, 또한 생체의 에너지 생성과정 및 생체물질의 생합성과 밀접하게 연관되어 있는 NAD(Nicotinamide adenine dinucleotide), NADPH(Nicotinamide adenine dinucleotide phosphate)의 생합성에도 관련이 있는 것으로 알려져 있다. 따라서 현재까지 니코틴아미드는 여러 연구자들에 의해 많은 연구가 진행되어 그 효과에 대한 특허 및 보고가 매우 많으며, 대표적인 예로는 모발과 손톱의 성장 촉진효과(US 537515), 슬리밍(slimming), 효과(DE 4401308 A), 미백효과(EP 396422), 피부를 밝게하는 효과(GB 2230186), 보습효과(JP 92277540)등은 각국의 특허에 출원되었으며, 이외에도 상처치유 효과, 파킨슨씨병 치유에 대한 효과, 진정효과, 세포 괴사 및 세포자살(apoptosis)억제효과, 라디칼 소거 효과등이 보고되어 있다(Ann-N-Y-Acad-Sci, 1996 Jun 15;786:135-51, Phamacol-Biochem-Behav. 1996 Apr;53(4):783-90, Am-J-Clin-Nutr. 1992 Jun;55:1208s-1214s, Cancer-Res. 1990 Apr 15;50(8):2470-5, Diabats-Res. 1990 Feb;13(2):67-73).Nicotinamide is a water-soluble substance with a molecular weight of 117, which is converted into vitamin B in vivo and is also closely related to the energy generation process and biosynthesis of biomaterials, Nicotinamide adenine dinucleotide phosphate (NADPH) It is also known to be involved in biosynthesis. Therefore, nicotineamide has been studied by many researchers so far, and there are many patents and reports on its effects. Examples of the nicotinamide include growth promoting effect (US 537515), slimming, and effect (DE) of hair and nails. 4401308 A), whitening effect (EP 396422), skin lightening effect (GB 2230186), moisturizing effect (JP 92277540), etc. have been filed in the patents of each country, in addition to wound healing effect, Parkinson's disease healing effect, soothing effect , Cell necrosis, apoptosis inhibitory effect, and radical scavenging effect have been reported (Ann-NY-Acad-Sci, 1996 Jun 15; 786: 135-51, Phamacol-Biochem-Behav. 1996 Apr; 53 ( 4): 783-90, Am-J-Clin-Nutr. 1992 Jun; 55: 1208s-1214s, Cancer-Res. 1990 Apr 15; 50 (8): 2470-5, Diabats-Res. 1990 Feb; 13 ( 2): 67-73).
그러나 본 발명에서 주장하는 효과인 아토피성 피부염 관련 균주에 대한 항균효과를 통한 아토피성 피부염 완화 효과에 대한 특허나 보고는 현재까지 없었으며, 이에 본 발명자는 이러한 항균 효능을 가진 니코틴아미드를 이용하여 아토피성 피부염 완화 효과에 대한 입증 실험을 한 결과 우수한 효과를 갖는 것을 알게 되어 최종적으로 본 발명을 완성 할 수 있었다.However, there have been no patents or reports on atopic dermatitis alleviating effects through antimicrobial effects on the atopic dermatitis related strains, which are claimed in the present invention, and thus the present inventors have used atopy using nicotinamide having such antimicrobial efficacy. As a result of the experimental experiments on the remission effect of sexual dermatitis, it was found that the excellent effect was finally able to complete the present invention.
본 발명은 니코틴아미드를 피부 외용 연고나 화장료, 다시 말하면 유연화장수, 영양화장수, 영양크림, 맛사지크림, 엣센스, 팩등에 첨가하는 것이다. 본 발명을 좀더 상세히 설명하면 상기 니코틴아미드를 건조 중량에 대하여 0.001%∼20%(W/W), 바람직하게는 1.0%∼10%(W/W)를 앞서 언급한 피부외용 연고나 화장료에 첨가한다. 상기 농도 이하에서는 실질적인 효과를 기대하기 어렵고, 그 이상의 효과가 증가되지 않았으며, 또한 제형상 및 제품 안정성에 영향을 미친다.The present invention is to add nicotinamide to an external skin ointment or cosmetics, that is, softening water, nourishing cosmetics, nutrition cream, massage cream, essence, packs and the like. In more detail, the nicotinamide is added in an amount of 0.001% to 20% (W / W), preferably 1.0% to 10% (W / W), based on the dry weight of the external skin ointment or cosmetics. do. Below this concentration it is difficult to expect a substantial effect, no further effect is increased and it also affects the formulation and product stability.
이하 본 발명을 다음의 실험 및 실시예로 더욱 상세히 설명하고자 한다. 그러나 본 발명이 하기의 예에만 국한되지 않음을 밝혀둔다. 본 실험에 사용된 니코틴아미드는 미국의 시그마(Sigma)사의 시약을 구입하여 사용하였다.Hereinafter, the present invention will be described in more detail with the following experiments and examples. However, it should be noted that the present invention is not limited to the following examples. Nicotinamide used in this experiment was used to purchase a reagent of Sigma (USA).
실험예 1Experimental Example 1
상기 니코틴아미드에 대하여 세균 증식 억제 실험은 아토피성 피부염에 주요 감염균주로 널리 알려진Epidermophyton floccosum, Staphylococcus aureus, Pityrosporum ovale에 대한 최소저해농도(Minimal inhibition concentration)을 측정하여 알아보았다. 그 결과는 하기 표 1과 같다.Bacterial growth inhibition experiments for the nicotinamide was determined by measuring the minimum inhibition concentration (Minimal inhibition concentration) for Epidermophyton floccosum, Staphylococcus aureus, Pityrosporum ovale, which are widely known as the main infectious strains for atopic dermatitis. The results are shown in Table 1 below.
상기와 같이 니코틴아미드는 아토피성 피부염을 악화시키는 대표적인 2차 감염세균에 대해서 뛰어난 생장억제 효과를 보였다. 이외에도 니코틴아미드는 피부 지질합성을 증가시키고, 특히 세라마이드의 합성을 크게 증가시켜 각질층의 장벽보호기능을 강화시킴과 동시에 피부 각질층의 수분 보유능을 증가시켜 아토피성 피부염 완화에 매우 유용한 것으로 나타났다.As described above, nicotinamide showed an excellent growth inhibitory effect against a representative secondary infection bacteria that exacerbate atopic dermatitis. In addition, nicotinamide has been shown to be very useful in relieving atopic dermatitis by increasing skin lipid synthesis, in particular, by increasing the synthesis of ceramides, enhancing barrier protection of the stratum corneum and increasing water retention of the stratum corneum.
상기와 같이 아토피성 피부염을 악화시키는 세균에 대한 항균력이 우수한 니코틴아미드를 사용한 각각의 조성으로 실시예를 실시하였다. 그러나 본 발명이 하기의 실시예에만 국한되지 않음을 거듭 밝혀둔다.As described above, the examples were carried out with the respective compositions using nicotinamide having excellent antimicrobial activity against bacteria which worsen atopic dermatitis. However, it should be noted that the present invention is not limited only to the following examples.
실시예 1Example 1
실시예 2Example 2
실시예 3Example 3
실험예 2Experimental Example 2
상기 실시예에 대하여 아토피성 피부염의 완화 효과를 다음과 같이 실시하였다. 10세에서 30세까지의 남녀 각각 15명을 대상으로 1일 2회씩 시료를 팔다리에 균일하게 도포하였고, 도포부위는 아토피성 피부염 질환이 발병하는 부위를 반반 나누어 1개월 동안 실시하였다. 피시험자의 발병부위 한 곳에는 니코틴아미트가 함유되어 있는 제제를 적용하였고, 또 다른 발병부위에는 니코틴아미드가 함유되어 있지 않은 대조군을 적용하여 실험하였다.In the above Example, the alleviation effect of atopic dermatitis was carried out as follows. Samples were applied to the limbs twice a day for 15 men and women aged 10 to 30 years, and the application site was performed for half a month by dividing the site of atopic dermatitis disease. In one site of the test subject, the preparation containing nicotine amit was applied, and another site was tested by applying the control group containing no nicotinamide.
1개월후 아토피성 피부염의 완화정도를 육안판정 및 시료적용전과 적용후의 환부 사진을 비교하여 분석하였다. 육안판정 기준은 각각의 기제 도포 대조군과 비교하여 개선없음, 약간의 개선, 중등도의 개선, 상당한 개선의 4단계로 판정하였으며 결과를 표 2에 나타내었다.After 1 month, the degree of relief of atopic dermatitis was analyzed by visual inspection and comparison of the affected areas before and after application. The visual judgment criteria were determined by four stages of no improvement, slight improvement, moderate improvement, and significant improvement compared to each base application control, and the results are shown in Table 2.
표 2에서 알 수 있는 바와 같이 본 발명에 의한 실시예들은 니코틴아미드가 함유되어 있는 모두의 경우에서 아토피성 피부염의 완화효과를 보여주고 있으며, 특히 상기 예의 80∼90%정도는 인지가 가능한 정도의 아토피성 피부염의 완화효과를 보여주었다.As can be seen in Table 2, the examples according to the present invention show the alleviation effect of atopic dermatitis in all cases containing nicotinamide. It has been shown to alleviate atopic dermatitis.
이상과 같이 아토피성 피부염 관련 균주에 대한 항균작용(실험예 1), 아토피성 피부염 완화효과(실험예 2)로 미루어 볼 때 니코틴아미드 함유 화장료는 아토피성 피부염에 유효한 효과가 있었으며 피부 부작용 및 아토피성 피부염 악화는 관찰되지 않았다. 이는 본 발명이 피부에 도포 외용제로 사용되었을 때 유전적 또는 외적인 요인에 의해 발생된 아토피성 피부염을 매우 효과적으로 경감해 줄 수 있다는 것을 의미한다.In conclusion, nicotinamide-containing cosmetics were effective in treating atopic dermatitis. No exacerbation of dermatitis was observed. This means that the present invention can very effectively alleviate atopic dermatitis caused by genetic or external factors when used as a topical application to skin.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020000007277A KR100653012B1 (en) | 2000-02-16 | 2000-02-16 | Cosmetic composition for the prevention and reduction of atopic dermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020000007277A KR100653012B1 (en) | 2000-02-16 | 2000-02-16 | Cosmetic composition for the prevention and reduction of atopic dermatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20000024485A true KR20000024485A (en) | 2000-05-06 |
| KR100653012B1 KR100653012B1 (en) | 2006-11-30 |
Family
ID=19646900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020000007277A KR100653012B1 (en) | 2000-02-16 | 2000-02-16 | Cosmetic composition for the prevention and reduction of atopic dermatitis |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100653012B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200009123A1 (en) * | 2018-07-03 | 2020-01-09 | The Procter & Gamble Company | Method of treating a skin condition |
| US11583488B2 (en) | 2020-06-01 | 2023-02-21 | The Procter & Gamble Company | Method of improving penetration of a vitamin B3 compound into skin |
| US11911498B2 (en) | 2020-06-01 | 2024-02-27 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7582398A (en) * | 1997-05-19 | 1998-12-11 | Rosemarie Scivoletto | Composition for treating skin conditions |
| JP3333428B2 (en) * | 1997-06-06 | 2002-10-15 | カネボウ株式会社 | External preparation for skin |
| KR100242858B1 (en) * | 1997-07-03 | 2000-03-02 | 손경식 | Hair shampoo composition for the treatment of itching or dandruff |
| KR19990024693A (en) * | 1997-09-05 | 1999-04-06 | 성재갑 | Nicotinamide-Containing Compositions for Wrinkle Relief |
| KR100525842B1 (en) * | 1997-11-19 | 2006-01-12 | 주식회사 엘지생활건강 | Nicotinamide-containing ceramide liquid crystal and cosmetic composition comprising the same |
-
2000
- 2000-02-16 KR KR1020000007277A patent/KR100653012B1/en active IP Right Grant
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200009123A1 (en) * | 2018-07-03 | 2020-01-09 | The Procter & Gamble Company | Method of treating a skin condition |
| US11622963B2 (en) * | 2018-07-03 | 2023-04-11 | The Procter & Gamble Company | Method of treating a skin condition |
| US11583488B2 (en) | 2020-06-01 | 2023-02-21 | The Procter & Gamble Company | Method of improving penetration of a vitamin B3 compound into skin |
| US11911498B2 (en) | 2020-06-01 | 2024-02-27 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100653012B1 (en) | 2006-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0954278B1 (en) | Pharmaceutical compositions containing kukui nut oil | |
| WO1996014085A1 (en) | External preparation for skin protection | |
| US20200330366A1 (en) | Cosmetic use of a protein extract of moringa oleifera seeds | |
| KR101494661B1 (en) | Composition for hair or scalp treatment comprising fermented black garlic residue and method of preparing the same | |
| KR20110083817A (en) | Cosmetic composition for improving dermatitis | |
| KR20090121102A (en) | Compositions comprising seaweeds extract for improving and alleviating inflammation and irritation of skin | |
| CN107670027B (en) | Compositions and methods for treating skin conditions | |
| KR100926047B1 (en) | Composition for Improving a Atopy Epidermal Inflammation | |
| KR20020076375A (en) | Cosmetics Useful for atopic skin | |
| KR100682979B1 (en) | Composition for precaution treatment having synergism for antimicrobial infection and antiinflammatory action and treatment for athletes foot provided by using them | |
| KR20070011939A (en) | Cosmetic material including extract of camellia flower for skin abirritation | |
| KR100653012B1 (en) | Cosmetic composition for the prevention and reduction of atopic dermatitis | |
| KR20120078810A (en) | Cosmetics composition for skin conditions comprising methyl sulfonyl methane, alum | |
| CA1270202A (en) | Moisture-retaining preparation for dermal use | |
| JP2002097151A (en) | Skin care preparation | |
| EP3378474B1 (en) | Composition for the use in the treatment of plantar hyperhidrosis predisposing to cutaneous fungal infection of the foot | |
| JP5414137B2 (en) | Hyaluronidase activity inhibitor | |
| KR20060054807A (en) | Cosmetics improving for atopy skin | |
| JP3516792B2 (en) | External preparation for skin | |
| JP4132351B2 (en) | Antiplasmin | |
| KR20160066733A (en) | COMPOSITION FOR MOISTURIZING THE SKIN CONTAINING (2S)-1-O-LINOLENOYL-3-O-β-D-GALACTOPYRANOSYL-SN-GLYCEROL | |
| KR20160067428A (en) | COMPOSITION FOR MOISTURIZING THE SKIN CONTAINING (2S)-1-O-LINOLENOYL-2-O-LINOLENOYL-3-O-β-D-GALACTOPYRANOSYL-SN-GLYCEROL | |
| KR20230135528A (en) | Cosmetic compositions comprising astaxanthin, epidermal growth factor and mixed extracts of natural product as effective components | |
| KR20160081160A (en) | Skin external composition for moisturizing or whitening the skin comprising compound K and panaxydol | |
| KR20160081163A (en) | Skin external composition for moisturizing or whitening the skin comprising compound K and icariside B2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| N231 | Notification of change of applicant | ||
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20120914 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20130913 Year of fee payment: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20140917 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20150917 Year of fee payment: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20160919 Year of fee payment: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20170928 Year of fee payment: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20180927 Year of fee payment: 13 |
|
| FPAY | Annual fee payment |
Payment date: 20191014 Year of fee payment: 14 |